文献速递前列腺癌

前列腺健康指数联合多参数磁共振预测主动监测中前列腺癌分级再分类

Prostate Health Index and multiparametric magnetic resonance imaging to predict prostate cancer grade reclassification in active surveillance.
PubMed 文献 · BJU Int · 2020-06-02

该回顾性研究纳入253例约翰霍普金斯主动监测(AS)项目中的前列腺癌患者,评估前列腺健康指数(PHI)联合多参数磁共振(mpMRI)预测分级再分类(GR)的价值。结果显示,PHI联合PI-RADSv2≤3可将GR的阴性预测值提升至98%,并可能避免20%的活检,但会遗漏2.6%的GR。

要点

  • PHI联合PI-RADSv2≤3对GR的阴性预测值达98%,AUC为0.70。
  • 联合策略可避免20%的监测活检,但会遗漏2.6%的GR。
  • GR患者PHI、PHID和PSAD均显著高于无GR者。

核心结论

  • PHI与mpMRI联合有助于预测AS患者的分级再分类,可能减少监测活检负担。

研究设计与样本

  • 回顾性研究,纳入2014至2019年约翰霍普金斯AS项目中253例连续患者,均接受mpMRI和PHI后行系统±靶向活检。

主要发现

  • 253例中38例(15%)发生GR;GR患者PHI为40.7 vs 32.0(P=0.001),PHID为0.83 vs 0.57(P=0.007),PSAD为0.12 vs 0.10(P=0.037)。
  • PI-RADSv2≤3单独预测GR的NPV为91.6%,AUC为0.67。
  • PI-RADSv2≤3联合PHI cut-off 25.6时,NPV和AUC分别提升至98%和0.70。
  • PI-RADSv2联合PSAD cut-off 0.07 ng/mL/mL时,AUC为0.69,NPV为95.4%。
  • PHI联合PI-RADSv2可避免20%的活检,但会遗漏2.6%的GR。

关键数值与推荐

  • GR定义为Gleason评分>6。
  • PHI cut-off为25.6,PSAD cut-off为0.07 ng/mL/mL,均取各自第一四分位数。

临床怎么用

  • 对于AS患者,可考虑联合PHI和mpMRI预测GR,辅助决策是否进行监测活检。

局限性

  • 回顾性单中心研究,样本量有限,结论需外部验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To identify the value of combining the Prostate Health Index (PHI) and multiparametric magnetic resonance imaging (mpMRI), tools which have previously been shown to be independently predictive of prostate cancer (PCa) grade reclassification (GR; Gleason score >6), for the purpose of predicting GR at the next surveillance biopsy to reduce unnecessary prostate biopsies for men in PCa active surveillance (AS). PATIENTS AND METHODS: Between 2014 and 2019, we retrospectively identified 253 consecutive men in the Johns Hopkins AS programme who had mpMRI and PHI followed by a systematic ± targeted biopsy. PHI and PHI density (PHID) were evaluated across Prostate Imaging-Reporting and Data System version 2.0 (PI-RADSv2) scores and compared to those with and without GR. Next, the negative predictive value (NPV) and area under the receiver operating curve (AUC) were calculated to compare the diagnostic value of PI-RADSv2 score combined with PHI, PHID, or prostate-specific antigen density (PSAD) for GR using their respective first quartile as a cut-off. RESULTS: Of the 253 men, 38 men (15%) had GR. Men with GR had higher PHI values (40.7 vs 32.0, P = 0.001), PHID (0.83 vs 0.57, P = 0.007), and PSAD (0.12 vs 0.10, P = 0.037). A PI-RADSv2 ≤3 alone had a NPV of 91.6% for GR (AUC 0.67). Using a PHI cut-off of 25.6 in addition to PI-RADSv2 ≤3, the NPV and AUC were both increased to 98% and 0.70, respectively. Using a PSAD cut-off of 0.07 ng/mL/mL with PI-RADSv2 had an AUC of 0.69 and NPV of 95.4%. PHI and PI-RADSv2 together could have avoided 20% of biopsies at the cost of missing 2.6% of GRs. CONCLUSIONS: The combination of PHI and mpMRI can aid in the prediction of GR in men on AS and may be useful for decreasing the burden of surveillance prostate biopsies.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Schwen ZR, Mamawala M, Tosoian JJ, et al. Prostate Health Index and multiparametric magnetic resonance imaging to predict prostate cancer grade reclassification in active surveillance. BJU Int. 2020. PMID: 32367635. doi:10.1111/bju.15101

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。